SKILLMAN, N.J., March 25, 2022 – Johnson & Johnson Consumer Inc. will present new research highlighting important advances in the understanding and treatment of skin at the 2022 American Academy of Dermatology (AAD) Meeting, taking place March 25-29 in Boston, MA. A total of 11 posters ranging from the effects of oat against environmental and anti-inflammatory triggers to a vitamin C serum with clinical benefits across diverse skin types will be presented at this year’s meeting.

“At Johnson & Johnson Consumer Health, we take pride in the breadth of our scientific solutions for healthier skin, which continue to evolve as the world around us does,” said Caroline Tillett, Global Head R&D, Johnson & Johnson Consumer Health. “In the past year, and through our critical research programs, we’re addressing consumer health needs across various skin states and types, including aging, sensitive, and hyperpigmented skin. Our new research – concerning external factors impacting skin such as environmental triggers and mental stress – demonstrates our commitment to innovating far beyond the visible layer.”

Grounded in science, Johnson & Johnson Consumer Health brings leading skincare products to consumers and healthcare professionals globally. Its recent skincare innovations include the Neutrogena® Rapid Wrinkle Repair Retinol Pro+ .5% Power Serum, an anti-aging facial serum that contains the brand’s highest concentration of 0.5% pure retinol in a skin-nourishing serum; the AVEENO Calm + Restore™ line which helps restore the skin’s moisture barrier with nourishing prebiotic oat; the Neutrogena® Stubborn line, which provides dermatologist-grade over-the-counter treatments for acne-prone and hyperpigmented skin; and the Exuviance® Age Reverse + Rebuild-5 formulated with 5 rejuvenating ingredients, including MicroDiPeptide229, for visibly firmer skin in just two weeks.

New science being highlighted at this year’s AAD meeting include:

• Poster #33555: High Concentration (15%) Vitamin C (Ascorbic Acid) Stabilized in Unique Aqueous Vehicle with Feverfew, Polyhydroxy Acid (PHA) and Epigallocatechin Gallate (EGCG) Provides Clinical Benefits for Hyperpigmentation in a Diverse Population
• Poster #33550: Topical Oat-Containing Formulations Provide Skin Protection Against Environmental and Inflammatory Triggers for Atopic Dermatitis In Vitro
• Poster #33131: Modeling Acute and Cumulative Erythemal Sun Exposure on Vulnerable Body Sites During Beach Vacations Utilizing Behavior Encoded 3D Body Models
• Poster #33562: Understanding Mental Stress and Skin Aging Connection Among Dermatologists and Psychologists Through Real-World Evidence
• Poster #33127: A Cross-Sectional Examination of Sunburn Incidence in the Context of Race/Ethnicity and Skin Type
• Poster #33559: Skin Maturation Processes Observed in Infants Extend Well into the Childhood Period
• Poster #33565: Clinically Proven Anti-aging Effects of a New Skincare Line and Retinol Tolerance Building Guidance for Asian Consumers
• Poster #33568: Evaluating the Mildness of Glycinate-based Cleanser Through in Vitro Methodologies and Computational Modeling
• Poster #33572: Real-world Evidence (RWE) on Sunscreen Compliance and Photodamage Perception Among Consumers and Dermatologists
• Poster #33576: How Lifestyle-Based Environmental Exposures Impact Skin Health through Microbiome
• Poster #33577: Novel 10% Multi-Acid Serum Provides Clinical Acne and Complexion Benefits in Subjects with Mild to Moderate Acne

“Skin is the body’s first line of defense, and our research over the past year has led to next-generation innovations that showcase new ways to treat and protect it,” said Menas Kizoulis, Director, Scientific Engagement, Johnson & Johnson Consumer Health. “From the treatment of skin conditions such as atopic dermatitis, to evaluating how mental stress impacts skin integrity, to a cutting-edge study using 3D modeling to look at external factors impacting skin, Johnson & Johnson Consumer Health is dedicated to taking an integrated approach to advancing and promoting skin health.”

Johnson & Johnson Consumer Health also announced it is collaborating with the American Academy of Dermatology on the launch of the “Pathways: Inclusivity in Dermatology” initiative to increase the number of practicing dermatologists in the U.S. who are from the Black, Latino, and Indigenous communities, which are underrepresented minorities (URM) in medicine.

For more information about the “Pathways: Inclusivity in Dermatology” program, please visit http://www.aad.org/pathways.

To learn more about the data Johnson & Johnson Consumer Health will be presenting at this year’s AAD Meeting, please visit the AAD website, here.

About the Consumer Health business of Johnson & Johnson

At Johnson & Johnson Consumer Health, we are driven to improve the personal health of people everywhere. Our differentiated portfolio of iconic brands, including Tylenol®, Zarbee’s®, Neutrogena®, Aveeno®, Listerine®, OGX®, and Johnson’s®, delivers life-enhancing, first-to-market innovation. By combining the power of science with meaningful human insights and digital-first thinking, we help more than 1.2 billion people live healthier lives every day, from their very first day.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding development of consumer health dermatological products. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Consumer Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays, internally or within the supply chain; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson Consumer Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Media Contact

Melissa Witt
Mwitt1@its.jnj.com